Literature DB >> 33128508

Neonatal complications of Down syndrome and factors necessitating intensive care.

Katelyn Seither1, Sammy Tabbah2, Dawit G Tadesse3, Kristen R Suhrie1,4.   

Abstract

Limited knowledge exists about how frequently newborns with Down syndrome receive a prenatal diagnosis, require intensive care, and what surgical and medical factors are contributory. A retrospective cohort study was performed for patients with a diagnosis of Down syndrome born in 2013 and 2014 who sought care at Cincinnati Children's Hospital Medical Center during the first year of life. Data were extracted from the electronic medical record through the first year of life including need for intensive care as a newborn, prenatal diagnosis, and medical and surgical complications. Of the 129 patients in the study, 65% required intensive care as newborns. The presence of a structural abnormality that required surgical correction in the neonatal period and certain types of congenital heart disease not requiring surgical intervention in the neonatal period were positively associated with the need for intensive care. A minority of infants, 8%, had a confirmed prenatal diagnosis. A majority of newborns with Down syndrome required intensive care following birth while a minority had any concern for the diagnosis prenatally. Improving prenatal diagnostic rates would allow for better prenatal counseling and delivery planning, while targeting therapeutic interventions for this population is needed to improve outcomes.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Down syndrome; intensive care; newborns; prenatal diagnosis

Mesh:

Year:  2020        PMID: 33128508     DOI: 10.1002/ajmg.a.61948

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  1 in total

1.  Morbidity and mortality in neonates with Down Syndrome based on gestational age.

Authors:  Emily A Messick; Carl H Backes; Kenneth Jackson; Sara Conroy; Stephen A Hart; Clifford L Cua
Journal:  J Perinatol       Date:  2022-09-21       Impact factor: 3.225

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.